Document is current
Any future updates will be listed below
-
Authors
,
van der Velden, Vincent H. J. http://orcid.org/0000-0001-9457-3763
,
Brüggemann, Monika
Cazzaniga, Giovanni
Scheijen, Blanca
Tops, Bastiaan
Trka, Jan
Pal, Karol
Hänzelmann, Sonja
Fazio, Grazia
Songia, Simona
Langerak, Anton W. http://orcid.org/0000-0002-2078-3220
Darzentas, Nikos
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG2015-17593)
KWF Kankerbestrijding (2017/11137)
- License Information
-
More Information
Article History
Received: 3 December 2020
Revised: 15 December 2020
Accepted: 22 January 2021
First Online: 19 February 2021
Compliance with ethical standards
:
: The EuroClonality-NGS Working Group is an independent scientific subdivision of EuroClonality that aims at innovation, standardization and education in the field of diagnostic clonality analysis. The revenues of the previously obtained patent (PCT/NL2003/000690), which is collectively owned by the EuroClonality Foundation and licensed to InVivoScribe, are exclusively used for EuroClonality activities, such as for covering costs of the Working Group meetings, collective WorkPackages and the EuroClonality Educational Workshops. The EuroClonality consortium operates under an umbrella of ESLHO, which is an official EHA Scientific Working Group. VHJvdV: contract research for Pfizer and Janssen, Service Level Agreements with BD Biosciences and Agilent. MB reports personal fees from Incyte (advisory board), financial support for reference diagnostics from Affimed, Amgen and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), personal fees from Janssen (speakers bureau), personal fees from Molecular Health (advisory board), all outside the submitted work. AWL: contract research for Roche-Genentech, research support from Gilead, advisory board for AbbVie, speaker for Gilead, Janssen. The other authors declare no conflict of interest.
